136 related articles for article (PubMed ID: 37480334)
21. A Mass Balance Study of
Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
[TBL] [Abstract][Full Text] [Related]
22. Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice.
Lee BS; Park SJ; Kim YB; Han JS; Jeong EJ; Son HY; Moon KS
Arch Toxicol; 2017 Jan; 91(1):453-464. PubMed ID: 27017489
[TBL] [Abstract][Full Text] [Related]
23. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Yamada O; Hirakata H
Ther Apher Dial; 2022 Apr; 26(2):345-356. PubMed ID: 34390314
[TBL] [Abstract][Full Text] [Related]
24. Enarodustat Treatment for Renal Anemia in Patients With Non-dialysis Chronic Kidney Disease.
Mima A
In Vivo; 2023; 37(2):825-829. PubMed ID: 36881056
[TBL] [Abstract][Full Text] [Related]
25. A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study.
Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
Kidney Dis (Basel); 2021 Nov; 7(6):494-502. PubMed ID: 34901195
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Hemoglobin Response to Treatment With Enarodustat Using Pharmacometric Approach in Japanese Anemic Patients With Chronic Kidney Disease.
Naruhashi S; Fujii T; Yamada H; Pai SM; Ninomiya N
J Clin Pharmacol; 2023 Feb; 63(2):180-196. PubMed ID: 36057843
[TBL] [Abstract][Full Text] [Related]
27. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
28. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
29. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
31. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
Pai SM; Yamada H
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):111-116. PubMed ID: 37975611
[TBL] [Abstract][Full Text] [Related]
32. Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.
Paranjpe MG; Denton MD; Vidmar TJ; Elbekai RH
Toxicol Pathol; 2015 Jul; 43(5):611-20. PubMed ID: 25391312
[TBL] [Abstract][Full Text] [Related]
33. Enarodustat: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
[TBL] [Abstract][Full Text] [Related]
34. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
[TBL] [Abstract][Full Text] [Related]
35. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
Ito M; Tanaka T; Ishii T; Wakashima T; Fukui K; Nangaku M
Kidney Int; 2020 Apr; 97(4):687-701. PubMed ID: 32033782
[TBL] [Abstract][Full Text] [Related]
36. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
37. Carcinogenicity and testicular toxicity of 2-bromopropane in a 26-week inhalation study using the rasH2 mouse model.
Goto Y; Saito A; Takanobu K; Senoh H; Saito M; Umeda Y; Yamano S
Sci Rep; 2023 Jan; 13(1):1782. PubMed ID: 36721063
[TBL] [Abstract][Full Text] [Related]
38. Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity Studies.
Darbes J; Sistare FD; DeGeorge JJ
Toxicol Pathol; 2015 Jul; 43(5):621-7. PubMed ID: 26047967
[TBL] [Abstract][Full Text] [Related]
39. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
[TBL] [Abstract][Full Text] [Related]
40. Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
Suguro M; Numano T; Kawabe M; Doi Y; Imai N; Mera Y; Tamano S
Toxicol Pathol; 2017 Apr; 45(3):427-434. PubMed ID: 28421967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
